Company officials said they’d employ California-based HeartFlow’s FFRct Analysis in a case series of robotic-assisted percutaneous coronary interventions to evaluate the technology’s role in clinical decision support. The testing will be done at hospitals in Michigan and Texas, according to an Oct. 23 news release.
The HeartFlow FFRct Analysis, designed to examine heart disease, uses angiogram data to create personalized digital 3D models of the patient’s coronary arteries. It would then develop computer algorithms to simulate blood flow and assess the effect of blockages on blood flow in the heart.
In August, HeartFlow won positive medical policies for its FFRct Analysis system from three separate Blue Cross Blue Shield providers. Also this year, it inked a collaborative deal with Royal Philips (NYSE:PHG) to promote its analysis system along with Philips’ catheters for assessing coronary arteries in patients with suspected coronary artery disease.
Corindus, which was founded in 2011, develops technology that performs robotic-assisted vascular surgeries. In March, the company employed 92 employees, according to a filing with the U.S. Securities & Exchange Commission.
In 2016, Corindus Vascular reported revenue of $2.8 million compared with $2.7 million in 2015, for a 3.7% increase.